Acute pancreatitis medical therapy
|
Acute pancreatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acute pancreatitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Acute pancreatitis medical therapy |
|
Risk calculators and risk factors for Acute pancreatitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]
Medical Therapy
Medical therapy in acute pancreatitis encompasses the four pillars of early management — fluid resuscitation, analgesia, nutrition, and antibiotic stewardship — as well as etiology-specific medical treatments (ERCP for biliary pancreatitis with cholangitis, triglyceride-lowering therapy for hypertriglyceridemic pancreatitis) and organ support in severe disease. Procedural and surgical interventions (step-up approach, necrosectomy, cholecystectomy) are addressed in the surgery/procedural therapy microchapter.
Fluid Resuscitation
Intravascular volume depletion from third-space losses contributes to organ failure and pancreatic necrosis. Fluid resuscitation to prevent hypovolemia and organ hypoperfusion is pivotal in the early management of acute pancreatitis.[1][2]
Rate and Volume
Moderately aggressive fluid resuscitation is recommended (ACG 2024: conditional recommendation, low quality of evidence).[1]
The WATERFALL trial (NEJM 2022) — a multicenter RCT of 249 patients — demonstrated that aggressive resuscitation (bolus 20 mL/kg followed by 3 mL/kg/h) resulted in significantly more fluid overload (20.5% vs 6.3%; adjusted RR 2.85; P=0.004) without improvement in the primary outcome of moderately severe or severe pancreatitis (22.1% vs 17.3%; adjusted RR 1.30; P=0.32). The trial was halted at the first interim analysis due to the safety signal.[3]
Moderate resuscitation protocol (from WATERFALL): 1.5 mL/kg/h with a 10 mL/kg bolus only if hypovolemia is present. Most patients will benefit from approximately 3–4 L in the first 24 hours, depending on body mass.[3]
Goal-directed titration: Fluid rate should be adjusted based on clinical targets (heart rate <120/min, MAP 65–85 mmHg, urine output >0.5 mL/kg/h) and biochemical targets (hematocrit 35–45%, BUN trending down). The ACG 2024 guidelines frame this as "do not miss the goal" therapy — do not allow BUN or hematocrit to rise during the first 24–48 hours.[1]
Timing: Early hydration (first 6–12 hours) is most effective. Once severe disease is established or after 48 hours, aggressive hydration may be harmful.[1][3]
Type of Fluid
Lactated Ringer solution is preferred over normal saline (ACG 2024: conditional recommendation, low quality of evidence). LR is hypothesized to have anti-inflammatory properties based on preclinical data — proposed mechanisms include calcium binding to nonesterified fatty acids and lactate-mediated reduction of pancreatic inflammation. The WATERLAND trial (NCT05781243), evaluating LR vs. normal saline on clinical outcomes, is currently underway.[1]
Cautions
Older adults and patients with cardiac or renal disease require careful monitoring for fluid overload, pulmonary edema, and abdominal compartment syndrome.[1]
Multiple studies and the WATERFALL trial have demonstrated that aggressive resuscitation increases fluid-related complications without improving outcomes, and may be associated with increased mortality in severe acute pancreatitis.[3][1][4]
Pain Management
Debilitating abdominal pain is the presenting symptom in over 90% of patients, but guidelines have historically provided little evidence-based direction. The UEG/EPC 2026 interdisciplinary guidelines represent the first GRADE-based recommendations specifically for pain management in acute pancreatitis.[5]
Key Principles
Multimodal analgesia is preferred, combining non-opioid and opioid agents.[5]
NSAIDs (e.g., diclofenac, ketorolac) are useful for their anti-inflammatory and analgesic properties, particularly in mild acute pancreatitis. A 2026 meta-analysis of 13 RCTs found NSAIDs provided pain relief comparable to opioids with lower local complications (RR 0.59; 95% CI 0.37–0.94). Avoid in patients with acute kidney injury or active peptic ulcer disease.[6]
Opioids form the cornerstone of severe pain management (UEG/EPC 2026: GRADE-based recommendation). Current evidence does not consistently demonstrate harm from opioids in acute pancreatitis, and safety concerns should not delay their timely use.[5] A 2026 Cochrane systematic review of analgesic agents in acute pancreatitis similarly highlighted the paucity of high-quality RCTs and the absence of definitive evidence favoring any single analgesic protocol, reinforcing the need for a multimodal approach.[7]
Buprenorphine demonstrated superior pain relief compared with diclofenac in a double-blind RCT (n=50 per group), with comparable side-effect profiles and lower rescue analgesia requirements.[8]
Pentazocine (a kappa-opioid agonist) was superior to diclofenac in another RCT, requiring significantly less rescue analgesia.[9]
Step-down approach: Rather than the traditional WHO step-up ladder (designed for cancer pain), a step-down approach — starting with potent analgesia and de-escalating — may be more appropriate for the acute, self-limiting pain of acute pancreatitis.[5]
Morphine safety: The traditional teaching that morphine is contraindicated in acute pancreatitis due to sphincter of Oddi spasm is not supported by clinical evidence. No clinical trial has demonstrated worse outcomes with morphine. However, given the availability of alternatives with better pharmacokinetic profiles (buprenorphine, pentazocine), morphine is not the preferred first-line opioid.[5][8]
Epidural analgesia: Small RCTs suggest improved pancreatic perfusion and better early pain relief in the first 24 hours, but no difference in length of stay or mortality. Given risks of catheter-related hypotension and epidural abscess, this is not routinely used.[5]
Nutrition
The traditional concept of "pancreatic rest" (NPO until pain resolution and enzyme normalization) has been definitively overturned. The pancreas is largely insensitive to meal stimulation during acute pancreatitis, and early enteral nutrition preserves gut mucosal integrity, reduces bacterial translocation, and decreases infectious complications.[10]
Early Oral Feeding
Oral feeding should be initiated as soon as tolerated — within 24 hours in mild acute pancreatitis — with a low-fat solid diet. Starting with clear liquids is not required. This approach reduces length of stay (ACG 2024: conditional recommendation; AGA 2018: moderate quality of evidence).[1][11]
Patient-reported hunger can guide the decision to initiate feeding.
It is unnecessary to wait for pain resolution or enzyme normalization before resuming a diet.[1][11]
Enteral vs. Parenteral Nutrition
Enteral nutrition is strongly preferred over TPN. A Cochrane meta-analysis of 8 RCTs (348 patients) demonstrated that enteral nutrition was associated with decreased mortality (RR 0.50; 95% CI 0.28–0.91), multiple organ failure (RR 0.55; 95% CI 0.37–0.81), and systemic infection (RR 0.39; 95% CI 0.23–0.65) compared with TPN.[10][12]
TPN is reserved for patients who cannot tolerate enteral feeding (paralytic ileus, bowel obstruction) and should be initiated within 72 hours if enteral nutrition is not feasible.[1]
Route of Enteral Feeding
If oral intake is not tolerated within 72 hours, nasoenteral tube feeding should be initiated.
Nasogastric and nasojejunal feeding are comparable in efficacy and safety (ACG 2024: key concept). Nasogastric tube placement is far easier and less expensive than nasojejunal placement, which requires endoscopy or interventional radiology.[1]
Nasojejunal feeding is preferred if there is digestive intolerance from delayed gastric emptying or gastric outlet obstruction.[1]
Predicted Severe AP
The PYTHON trial (208 patients with predicted severe acute pancreatitis) showed that early enteral nutrition within 24 hours did not reduce infection (25% vs 26%) or mortality (11% vs 7%) compared with on-demand oral diet initiated at 72 hours. Thus, in predicted severe AP, oral diet should be attempted at 72 hours (or earlier if tolerated), with tube-based enteral nutrition initiated if not tolerated.[1][2]
Standard polymeric feeding formulations are preferred over the more expensive semi-elemental formulations; comparable feeding tolerance, diarrhea, and infection rates have been demonstrated.[1]
Pancreatic enzyme supplementation should be considered in patients with proven or suspected exocrine pancreatic insufficiency.[2][1]
Antibiotic Stewardship
No Role for Prophylactic Antibiotics
Multiple double-blind, placebo-controlled RCTs and meta-analyses have consistently demonstrated that prophylactic antibiotics in severe acute pancreatitis or sterile necrosis do not reduce rates of infected necrosis, systemic complications, mortality, or need for surgical intervention (ACG 2024: conditional recommendation against, very low quality of evidence for severe AP; key concept for sterile necrosis).[1][13]
Prophylactic antifungal therapy is also not recommended. Antifungals should be started only for documented fungal infection.[1]
Probiotics are not recommended. The PROPATRIA trial found increased mortality with enteral probiotics in predicted severe AP, and current guidelines advise against their use.[1]
Antibiotics for Extrapancreatic Infection
Antibiotics should be given for extrapancreatic infections (cholangitis, catheter-related infections, bacteremia, UTI, pneumonia) — this is distinct from prophylaxis of pancreatic necrosis. When infection is suspected, antibiotics should be started while the source is being confirmed and discontinued if cultures are negative (ACG 2024).[1]
Antibiotics for Suspected Infected Necrosis
Infected necrosis should be suspected in patients who deteriorate or fail to improve after 7–10 days, with persistent fevers, rising inflammatory markers, or gas on CT.[1][2]
Initiate broad-spectrum IV antibiotics with good pancreatic penetration: carbapenems, piperacillin-tazobactam, quinolones, metronidazole, and third-generation or higher cephalosporins. A 2026 review confirmed that non-carbapenem beta-lactams (piperacillin-tazobactam, cefepime) may achieve adequate tissue penetration when administered as extended infusions, offering an alternative to carbapenems.[14]
In clinically stable patients, antibiotics alone can serve as initial management for up to 4 weeks to allow the inflammatory reaction to organize before intervention. A substantial proportion of patients have been managed successfully with antibiotics alone.[1]
Procalcitonin-guided antibiotic stewardship: The PROCAP trial — a single-centre, patient-blinded RCT of 260 patients (Lancet Gastroenterol Hepatol 2022) — used procalcitonin testing (threshold 1.0 ng/mL) to guide antibiotic initiation, continuation, and discontinuation. Antibiotic use was significantly lower in the procalcitonin-guided group (45% vs 63%; adjusted risk difference −15.6%; 95% CI −27.0 to −4.2; P=0.007), with fewer antibiotic days and no increase in clinical infections or mortality. Further multicenter validation is needed before routine adoption.[2]
The microbiological spectrum is predominantly enteric (E. coli, Klebsiella spp., Enterococcus, Candida). Prolonged hospitalization and antibiotic exposure select for resistant organisms.[1]
ERCP in Biliary Acute Pancreatitis
Concurrent cholangitis: Urgent ERCP within 24 hours is indicated (ACG 2024: key concept).[1]
Progressive cholestasis without cholangitis: ERCP may be considered when bilirubin is rising (>3–5 mg/dL) in the setting of severe or moderately severe AP.[1]
Biliary pancreatitis without cholangitis or ongoing obstruction: ERCP is not recommended. The APEC trial (Schepers et al., Lancet 2020) demonstrated no reduction in the composite endpoint of major complications or mortality with urgent ERCP (38% vs 44%; RR 0.87; 95% CI 0.64–1.18).[15]
Screening for choledocholithiasis: Use MRCP or EUS rather than diagnostic ERCP when cholangitis is absent (ACG 2024: conditional recommendation).[1]
Management of Hypertriglyceridemic Acute Pancreatitis
Hypertriglyceridemia (TG ≥1,000 mg/dL) is the third most common cause of acute pancreatitis (~4.7–7% of cases) and is associated with more severe disease compared with other etiologies.[16]
Insulin infusion is the first-line triglyceride-lowering therapy. Insulin enhances lipoprotein lipase activity, promoting chylomicron clearance. Typical protocols use 0.1–0.3 units/kg/h IV insulin with dextrose infusion to maintain normoglycemia. TG reductions of ~50% within 24–48 hours are achievable.[17]
Therapeutic plasma exchange (TPE) achieves more rapid TG reduction (~70% vs ~50% within 24 hours) but a 2022 meta-analysis of 15 studies (909 patients) found no significant differences in complications, length of stay, or mortality compared with insulin. Insulin was associated with significantly fewer adverse events and lower cost.[18]
TPE should be considered in severe HTG-AP when insulin fails to lower TG adequately, and during pregnancy (where insulin and TPE are both considered safe).[1]
Heparin (low-molecular-weight preferred) activates lipoprotein lipase and may be combined with insulin. An RCT of 166 patients (He et al., JAMA Netw Open 2025) showed LMWH plus insulin achieved target TG levels (<500 mg/dL) within ~48 hours with reduced respiratory failure compared with hemofiltration.[19]
Long-term management: Initiate fibrates (fenofibrate or gemfibrozil) and omega-3 fatty acids before discharge; dietary counseling (very low-fat diet); address secondary causes (diabetes, medications, alcohol).[1]
No consensus guidelines currently define optimal early triglyceride-lowering therapy — insulin is most widely used based on accessibility, cost, and comparable outcomes.[1]
ICU and Organ Support
Patients with organ failure (modified Marshall score ≥2 in any system) should be admitted to an ICU or monitored setting (ACG 2024: strong recommendation).[1]
Organ support follows standard critical care principles: mechanical ventilation for ARDS, vasopressors for refractory hypotension, renal replacement therapy for AKI.[1]
Monitor for abdominal compartment syndrome in patients with massive fluid resuscitation and abdominal distention — bladder pressure monitoring is indicated when intra-abdominal hypertension is suspected.[1]
VTE prophylaxis should be provided to all hospitalized patients per standard protocols.[1]
Clinically Actionable Recommendations
- Use moderately aggressive fluid resuscitation with lactated Ringer solution (~1.5 mL/kg/h; bolus 10 mL/kg if hypovolemic). Do not allow BUN or hematocrit to rise. Avoid aggressive protocols (≥3 mL/kg/h).[1][3]
- For pain, use a multimodal approach; do not withhold opioids for severe pain. Safety concerns about opioids in acute pancreatitis are not supported by evidence.[5]
- Initiate early oral feeding with a low-fat solid diet as soon as tolerated. Do not wait for pain resolution or enzyme normalization.[1][11]
- Do not use prophylactic antibiotics in sterile necrosis. Use therapeutic antibiotics only when infected necrosis is clinically suspected.[1]
- Perform urgent ERCP within 24 hours only for concurrent cholangitis.[1]
- For hypertriglyceridemic pancreatitis, start IV insulin infusion as first-line TG-lowering therapy; reserve TPE for refractory cases or pregnancy.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 1.32 1.33 1.34 1.35 1.36 Tenner S, Vege SS, Sheth SG; et al. (2024). "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis". Am J Gastroenterol. 119 (3): 419–437. doi:10.14309/ajg.0000000000002645.
- ↑ 2.0 2.1 2.2 2.3 2.4 Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE (2024). "Diagnosis and Management of Acute Pancreatitis". Gastroenterology. 167 (4): 673–688. doi:10.1053/j.gastro.2024.02.052.
- ↑ 3.0 3.1 3.2 3.3 3.4 de-Madaria E, Buxbaum JL, Maisonneuve P; et al. (2022). "Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis". N Engl J Med. 387 (11): 989–1000. doi:10.1056/NEJMoa2202884.
- ↑ McDermott J, Kao LS, Keeley JA, Nahmias J, de Virgilio C (2024). "Management of Gallstone Pancreatitis: A Review". JAMA Surg. doi:10.1001/jamasurg.2024.2580.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Pandanaboyana S, Knoph CS, Kuhlmann L; et al. (2026). "European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations". United European Gastroenterol J. PMID 42299777 Check
|pmid=value (help). - ↑ Bandyopadhyay S, Khan R, Samajdar SS, Banerjee A (2026). "Early Analgesia for the Management of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Pancreas. PMID 42153651 Check
|pmid=value (help). - ↑ Joseph N, Betts C, Tingle SJ; et al. (2026). "Analgesic agents versus placebo, no intervention, or alternative analgesic regimens in acute pancreatitis". Cochrane Database Syst Rev.
- ↑ 8.0 8.1 Saini M, Samanta J, Kumar A; et al. (2024). "Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial". Clin Gastroenterol Hepatol. 22 (3): 532–541.e8. doi:10.1016/j.cgh.2023.10.021.
- ↑ Mahapatra SJ, Jain S, Bopanna S; et al. (2019). "Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial". Am J Gastroenterol. 114 (5). PMID 31008736.
- ↑ 10.0 10.1 Mederos MA, Reber HA, Girgis MD (2021). "Acute Pancreatitis: A Review". JAMA. 325 (4): 382–390. doi:10.1001/jama.2020.20317. PMID 33496779 Check
|pmid=value (help). - ↑ 11.0 11.1 11.2 Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN (2018). "American Gastroenterological Association Institute Guideline On Initial Management of Acute Pancreatitis". Gastroenterology. 154 (4): 1096–1101. doi:10.1053/j.gastro.2018.01.032.
- ↑ Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA (2010). "Enteral versus parenteral nutrition for acute pancreatitis". Cochrane Database Syst Rev (1): CD002837. doi:10.1002/14651858.CD002837.pub2.
- ↑ Baron TH, DiMaio CJ, Wang AY, Morgan KA (2020). "American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis". Gastroenterology. 158 (1): 67–75.e1. doi:10.1053/j.gastro.2019.07.064.
- ↑ Pauw HS, Schwarz R, Beij A; et al. (2026). "Antimicrobial Therapy for Infected Necrotizing Pancreatitis: Microbiology, Antimicrobial Resistance and Pharmacokinetics". J Antimicrob Chemother. PMID 41808660 Check
|pmid=value (help). - ↑ Schepers NJ, Hallensleben NDL, Besselink MG; et al. (2020). "Urgent Endoscopic Retrograde Cholangiopancreatography With Sphincterotomy Versus Conservative Treatment in Predicted Severe Acute Gallstone Pancreatitis (APEC): A Multicentre Randomised Controlled Trial". Lancet. 396 (10245): 167–176. doi:10.1016/S0140-6736(20)30539-0.
- ↑ Yacine N, Chauv S, Peng MR; et al. (2026). "Evaluation of a Fixed-Dose Insulin Protocol for Hypertriglyceridemia-Induced Acute Pancreatitis: A Retrospective Cohort Study". Clin Endocrinol. doi:10.1111/cen.15244.
- ↑ Gubensek J (2023). "The Role of Apheresis and Insulin Therapy in Hypertriglyceridemic Acute Pancreatitis — A Concise Review". BMC Gastroenterol. 23: 339. PMID 37789261 Check
|pmid=value (help). - ↑ He W, Ding L, Liu Z; et al. (2022). "Insulin or Blood Purification Treatment for Hypertriglyceridaemia-Associated Acute Pancreatitis: A Systematic Review and Meta-Analysis". Pancreatology. 22 (8): 1092–1104. PMID 35981949 Check
|pmid=value (help). - ↑ He W, Cai W, Yang X; et al. (2025). "Low-Molecular-Weight Heparin Plus Insulin in Hypertriglyceridemic Acute Pancreatitis: A Randomized Clinical Trial". JAMA Netw Open. doi:10.1001/jamanetworkopen.2025.43900.